News & events.

Our CEO & Founder Dr. Wahid Awad took part in the Universités Pharmaceutiques 2026 in Paris, speaking in the session "La 'vraie vie' des entrepreneurs" alongside Arthur Delapalme (Codoc) and Paul Rinaudo (ADLIN), moderated by Stéphane Tholander. The round table offered a candid look at the realities of building a healthtech company: day-to-day challenges, regulatory complexity and strategic trade-offs, but also the resilience and conviction that drive healthcare innovation forward. The session was part of a broader dialogue with key stakeholders of the healthcare ecosystem, including Hélène Guimiot (CNIL) and David Sainati (French Ministry of Health), on the real-world conditions required to innovate in healthcare. At Rosetta Omics, we believe advancing precision oncology requires strong collaboration across the entire ecosystem, from regulators to clinicians, researchers and innovators.

Our founder & CEO Dr. Wahid Awad spoke at BNP Paribas' Data Week during a webinar on "AI in ESG and Health", alongside experts from BNP Paribas, CIB and CPBS. The session explored how AI is transforming decision-making, sustainability and healthcare, and why high-quality, trusted data remains the foundation of meaningful innovation. Dr. Awad shared our vision of how AI and multiomics can help oncologists better predict treatment response and personalize cancer care, stressing that AI is only as powerful as the data behind it and that trust, transparency and scientific validation are essential to its adoption in healthcare. Thank you to BNP Paribas and to moderator Margaux Lafontaine for the invitation.

As Rosetta Omics continues to grow, we are delighted to welcome two new interns: Emma François, from SupBiotech (école de biotechnologies), and Shona Park, from University of California, Berkeley. We believe innovation thrives when diverse perspectives come together, and we look forward to the ideas, energy and enthusiasm they will bring, while training a new generation of precision medicine professionals. Welcome to Rosetta Omics, Shona and Emma!

• Emma François: Biotechnology Engineering student at SupBiotech
• Shona Park: Molecular and Cell Biology student at UC Berkeley
• Both contribute to market research, competitive analysis and partnerships scouting
• First day captured at STATION F, Paris

Our CEO Wahid Awad joined an inspiring roundtable at VivaTech Paris on scaling AI in healthcare, alongside experts from Université Paris Cité and H Company. Key discussions centered on Europe's leadership potential, the importance of public-private partnerships, and our mission to leverage AI and multiomics for precision oncology. Thank you to Bpifrance and La French Care for hosting this impactful session.

Selected as a Deep Tech Pioneer 2026 for the second year, our CEO Dr. Wahid Awad joins one of the world's leading deep tech gatherings, alongside Investor Day on 10 June, to showcase how multimodal data and AI deliver more precise, actionable insights for cancer care.

The Rosetta Omics team joins founders, clinicians, researchers, investors and industry leaders advancing precision oncology, sharing how we combine AI and multiomics to uncover insights hidden within complex cancer data.

Rosetta Omics will attend BioLabs Europe Investor Day, part of European DeepTech Week, to connect with investors and strategic partners interested in advancing AI-driven precision oncology and our spatial and multi-omics clinical platform.

Organized by Bpifrance and EuroQuity, European DeepTech Week is a key gathering for founders, investors, corporates and innovation leaders. Rosetta Omics will connect with partners and investors who share a long-term vision for European deeptech leadership.

With action comes hope! We met visitors at our stand in the health section, in partnership with UM6P GLOBAL HUBS France. Special thanks to Mr. Jean-Pierre Farandou (Ministre du Travail et des Solidarités de France) for stopping by and for the great conversation. We were also delighted to introduce our new team member Aurore Ducamp. Rosetta Omics is changing the paradigm of cancer care by unlocking the road to precision medicine.

Rosetta Omics has been chosen as one of the finalists invited to pitch at the prestigious WHX Dubai. Our CEO will be pitching on 10 February in the biotech and life sciences category, looking to meet visionary investors, hospitals, pharma, biotech and medtech players.

Rosetta Omics will be at the 10th edition of this flagship e-health event, on the Pfizer Healthcare Hub France booth alongside Pfizer, WILCO Healthcare and the 5 other startups from the 5th cohort, to discuss our AI-enabled precision oncology solutions.

Hamid Idrissi, a seasoned Regulatory Affairs and Quality leader with 20+ years of experience across medical devices, biopharma, IVDs, CDx, and AI-ML SaMD technologies, joins the Rosetta Omics Advisory Board.

• VP Regulatory/Quality/Clinical at Amia.ai
• Expert in PMA, 510(k), IDE, De Novo, Q-Submissions, IND, BLA, NDA pathways
• Strong knowledge of EU MDR/IVDR and global registrations across EMEA, Asia, Japan, Australia, Canada & LATAM
• Approvals across IVDs, CDx, ICDs, biosimilars and AI-enabled software products

In partnership with ESCP Business School and UBC Sauder School of Business (Canada), an outstanding group of MBA students worked with Rosetta Omics on a strategic consulting project exploring our potential expansion into North America and India.

• Academic Director: Prof. Harish Krishnan (UBC Sauder)
• Students: Manmohan Singh, Manaal Zar, Seerat Dhaliwal, Dimitri Djuricic, Rafat Islam
• Market analysis, strategic recommendations, and global perspective for North America and India
• Visit and STATION F tour facilitated by UM6P GLOBAL HUBS – France

Dr. Wahid Awad attended this leading academic event focused on early-phase cancer research.

A cross-border event uniting biotech, medtech and digital health, connecting the tri-national ecosystem of Switzerland, France and Germany. Co-organized by University of Basel, Quest for Health, Life Science Accelerator Baden-Württemberg and BadenCampus.

We met investors, biotech and pharma leaders to advance partnerships in oncology and precision medicine.

Rosetta Omics was selected for the Biotechnology Venture Readiness Program 2025, opening doors in the GCC and MENA regions.

• Selection followed exchanges at the KSA Pavilion, BIO International Convention
• Mentorship from KOLs, investors and SFDA representatives
• Final showcase event in Riyadh, December 2025

An acceleration program by Pfizer and WILCO: 9 months of personalised mentorship to amplify our impact.

• Cohort of 6 startups improving patients' and caregivers' lives
• Demonstrating value for anti-cancer drug developers
• Biomarker discovery, target validation and treatment-response prediction

Rosetta Omics joined the ESAC (European Society for Advanced Cancer) Network to strengthen its position in European oncology innovation.

• European network of advanced cancer researchers and clinicians
• Collaborations across leading academic and industrial partners
• Reinforces our European footprint in precision oncology

Dr. Wahid Awad attended the 11th SFMPP (Société Française de Médecine Prédictive et Personnalisée) Congress on AI and Genomics: the twin drivers of medical innovation and personalization.

Our CEO briefly told President Emmanuel Macron at Adopt AI that Rosetta Omics is ready to be France's next AI-in-health champion and a global game changer in precision medicine. We are now raising funds to grow.

A productive exchange that led to our selection in the Saudi Biotechnology Venture Readiness Program 2025.

A strategic collaboration with the University of Strasbourg, ESBS and INSERM begins as Prof. Bagnard joins our Scientific Advisory Board.

• Renowned neuroscientist focused on brain development, neuronal connectivity and neurodegeneration
• Expert in biomarker-driven drug design bridging neurobiology and oncology
• Combines transcriptomics, proteomics and molecular imaging for diagnostic and predictive biomarkers

Third International Consulting Project (ICP) with ESCP designs Rosetta Omics' go-to-market strategy in the USA.

• Executive MBA team worked nearly a year on US market entry
• Project supervised by Prof. Frédéric Jallat (KPMG Chair, ESCP)
• Mentored by ESCP Alumni Stefano Scarafiotti and Elena Ivanchenko

Rosetta Omics was awarded the 1st European Innovation Prize among the top 20 European companies at HTID 2025 in Paris.

• 6th edition of HTIDs by HealthTech For Care
• Selected jury of top KOLs in healthcare
• Validation of our spatial multiomics + AI approach

Leonardo Cunha joins our Business Advisory Board, bringing global expertise in M&A, growth strategy, and internationalisation.

• Senior leadership across Europe, Americas and Asia
• MBA from Northwestern University – Kellogg School of Management
• Early angel investor in Rosetta Omics

Dr. Wahid Awad participated in the AI & Cancer Sector Day at Bercy, fostering dialogue across France's oncology innovation ecosystem.

• Held at Ministère de l'économie et des Finances, Paris
• Brought together public and private actors of the oncology ecosystem
• Showcased Rosetta Omics' contribution to French AI for health

Rosetta Omics attended BIG 2025 (Bpifrance Inno Generation), the largest deeptech conference organized by Bpifrance, after participating in the 2022, 2023 and 2024 editions. An opportunity to meet Bpifrance, the European Commission, and entrepreneurs from across Europe and the world.

We received the 1st European Innovation Prize among the top 20 European companies.

Our CEO Dr. Wahid Awad participated in AI4Immuno-Oncology: Advancing Cancer Care Through AI, co-organized by Future4care and Paris Saclay Cancer Cluster, exploring how AI is transforming cancer research, therapy design and personalized treatment.

Rosetta Omics completed its first POC study in Colon Cancer, validating its predictive multiomics approach.

• Integrates spatial multiomics, clinical records and AI
• Aims to enhance prediction of treatment responses
• Supports pharma partners in biomarker and target discovery

Dr. Wahid Awad was elected Executive Board Member of Medicen Paris Region, representing pharma, biotech, medtech and diagnostics SMEs.

• Founded in 2005, Medicen is the Île-de-France global competitiveness cluster
• Goal: position Paris as a European industrial leader in health innovation
• Translational medicine and leading-edge health technologies

Prof. Magali Svrcek, world expert in gastro-intestinal pathology and AI in pathology, joined our Scientific Advisory Board.

• Full Professor at Saint-Antoine Hospital, Paris
• Expert in colorectal, gastric and pancreatic cancers
• Pioneer in integrating AI into diagnostic pathology

We completed our second POC study in CRC, three times the size of the first, in partnership with a major French university hospital.

• Confirms results of the first POC study
• Larger cohort with hospital-grade data
• Strengthens evidence for treatment-response prediction

Our CEO joined the RAISE Summit, a unique gathering of innovators, scientists, investors and policy leaders shaping the future of AI and deep tech, with a focus on how AI and molecular data can drive meaningful change in healthcare.

Dr. Wahid Awad participated in the 4th edition of the Viv Healthtech conference in Bordeaux.

• Workshops, round tables and B2B meetings
• Backed by Région Nouvelle-Aquitaine and Bordeaux Métropole
• Connections with French healthtech innovators and investors

Our CEO Dr. Wahid Awad was a speaker at the AI Summit hosted by Aimfluance, sharing insights on how AI is revolutionizing healthcare via Rosetta Omics.

Rosetta Omics joined Europe's largest tech event to showcase how AI and spatial multiomics are reshaping oncology.

Our CEO attended the Onco Startup Summit, part of the 8th French Oncology Interdisciplinary Days, jointly organized by Angels Santé, Gustave Roussy Transfert, Paris Saclay Cancer Cluster, MATWIN, OncoSTART and Réseau SATT, bringing together 200+ oncology innovation leaders.

Our CEO took part in one of the most vibrant innovation events in Europe, representing our mission to revolutionize cancer care through multiomics and AI alongside scientists, entrepreneurs, investors and R&D leaders.

Our CEO joined 5,500+ participants from 53 countries at the second edition of the Deep Tech Summit, exploring the transformative impact of AI on deep tech across health, energy, agriculture and governance.

Our CEO Dr. Wahid Awad spoke at the NextAfrica, Tech & Health panel and represented Rosetta Omics at the UM6P exhibition booth as part of the Next Africa program bridging Africa and Europe, discussing AI for equitable healthcare in Africa.

Rosetta Omics was selected among the Deep Tech Pioneers, out of 4,600 applications from 120 countries.

• Recognised among the most promising deeptech ventures
• Year-round access to Hello Tomorrow community
• Visibility with global deeptech investors

Dr. Tanya Aneichyk, founder & CEO of OmicsChart, joins the Advisory Board to support our biomarker and pharma strategy.

• Visionary leader in cancer omics data sharing
• Background at Harvard Medical School and Mass General
• Expert in AI-driven diagnostics and pharma partnerships

Selected among the Deep Tech Pioneers, we connected with leading deeptech investors and operators worldwide.

Anne De Landsheer joins the Advisory Board, bringing 16+ years in pharma executive search and talent management.

• Founder of PEAK LIFECYCLES HR (Europe & US)
• Former lead of Korn Ferry's Life Sciences Practice
• Board member at REGEnLIFE (Medtech)

Rosetta Omics joined the first cohort of the UM6P #NextAfrica program, partnered with STATION F and WILCO.

• Bridge between Europe and Africa for deeptech
• Collaborations with Moroccan and African hospitals
• Bringing precision oncology to African patients

Rosetta Omics partnered at the RESI conference during the J.P. Morgan Healthcare Week in San Francisco, USA.

• Premier global healthcare investor week
• Exposure to US biotech, pharma and VCs
• Strategic step in our US expansion

Dr. Hatem Azim, leading medical oncologist and clinical development consultant, joined our Scientific Advisory Board.

• Former CMO at Emergence Therapeutics, VP at Innate Pharma
• Senior faculty at the European School of Oncology
• PhD from Université libre de Bruxelles

Rosetta Omics expands its strategic advisory board with esteemed international KOLs from the pharmaceutical industry. Dr. Hugues Renaut, PhD/MBA, joins the board.

• 30+ years in pharma (Servier) across Europe, Canada, China, South-America, Africa & Middle East
• Former vice-chair of EFPIA European Market Committee and Patient Access Committee member
• Now supports healthcare innovations as business angel (LBAN, Angels Santé) and through Health Care Advisory
• Will help drive Rosetta Omics' development in precision medicine

Dr. Wahid Awad pitched Rosetta Omics to investors during the HealthTech Investor Summit in Bruges, Belgium.

• Hosted by MEDVIA with 23 sponsors
• Direct access to European healthtech investors
• Showcase of Rosetta Omics' deeptech approach

Dr. Antoine Hollebecque, senior medical oncologist at Gustave Roussy, joins our Scientific Advisory Board.

• Principal investigator on 50+ Phase I/II/III clinical trials
• Expert in biliary, pancreatic carcinomas and FGFR inhibitors
• Author of 230+ peer-reviewed publications

Dr. Mohamed Amine Bani from Gustave Roussy joins our Advisory Board to deepen our pathology expertise.

• Pathologist at Gustave Roussy
• Champion of physician-driven product design
• Expanding our reach to oncologists and surgeons

First International Consulting Project with ESCP launched at the Agoranov incubator with a top-tier Executive MBA team.

• 12-month go-to-market strategy project
• Supervised by Prof. Frédéric Jallat
• Team of 5 EMBA candidates from across Europe

Rosetta Omics secured a Bpifrance BFT Émergence grant to finance two proof-of-concept studies in solid tumors.

• Non-dilutive deeptech grant
• Funds two POC studies on solid tumors
• Part of the France 2030 deeptech plan

Rosetta Omics joined the prestigious Agoranov incubator in Paris.

• Leading French incubator for deeptech and life sciences
• Mentorship, resources and ecosystem access
• Major milestone for our growth in France

Rosetta Omics joined France Biotech, the leading voice of the French biotech ecosystem.

• Access to a network of biotech leaders in France
• Stronger ties with French healthcare industry
• Support for innovation, investment and policy advocacy

Rosetta Omics joined a €1.5M consortium led by Maastricht University on early detection of osteoarthritis.

• Consortium with INIBIC, RIVM, OAFI and others
• Funded under the Dutch KIC call (NWO + Arthritis Society)
• Develops circulating epigenetic and protein biomarkers

Rosetta Omics is featured in the 3rd edition of the AI for Health French Startups Mapping.

• 191 key players across 10 categories
• Recognition in Predictive Health & Early Diagnosis
• Snapshot of France's healthcare AI ecosystem

Dr. Wahid Awad pitched Rosetta Omics at the entrepreneurship festival of ESCP's Blue Factory incubator.

• Theme: "Open Your Horizons"
• ESCP EMBA program ranked #3 worldwide by FT 2023
• Booth and pitch in front of festival attendees

Dr. Wahid Awad gave a guest lecture on entrepreneurship in biopharma at Grenoble Ecole de Management.

• Invited by Prof. Vittorio De Pedys
• Advanced Master in Biomedical Management students
• Strong interest from pharma/biotech professionals